Loading
Metastasis and Carcinoma Case Studies / Mechanisms of Cancer Metastasis / Chromatin Remodeling and Cancer · Journal article
Frontiers in Oncology · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single case report of a 49-year-old male with stage IV SMARCA4-deficient NSCLC who achieved rapid response to nab-Paclitaxel, cisplatin, and bevacizumab but died of disease progression with brain metastases at 12 months overall survival. The report documents a rare tumor type and treatment outcome but provides no evidence on efficacy, no control group, and no basis for comparing this result to standard care or prognosis.
Single case report. One 49-year-old Asian male with stage IV SMARCA4-deficient non-small cell lung cancer.. Intervention: Combination chemotherapy: nab-Paclitaxel, cisplatin, and bevacizumab. n = 1.
49-year-old Asian male with stage IV SMARCA4-deficient NSCLC demonstrated rapid response to nab-Paclitaxel, cisplatin, and bevacizumab combination Overall survival approximately 12 months, with death from brain metastases and treatment failure
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case provides descriptive information about one patient's treatment response and outcome but cannot guide clinical decision-making; clinicians should view it as anecdotal evidence in a rare disease. The report indicates that chemotherapy with anti-angiogenic therapy may warrant exploration in SMARCA4-deficient NSCLC, but efficacy remains unknown.
A single case report of an uncommon tumor type with no control group, describing one patient's response and outcome; contributes descriptive data but cannot establish efficacy or guide practice.
As stated by the source record.
Quoted from the source exactly as published.
This case provides descriptive information about one patient's treatment response and outcome but cannot guide clinical decision-making; clinicians should view it as anecdotal evidence in a rare disease. The report indicates that chemotherapy with anti-angiogenic therapy may warrant exploration in SMARCA4-deficient NSCLC, but efficacy remains unknown.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) is an uncommon malignant epithelial neoplasm originating in the lung, characterized by poorly differentiated and highly invasive pathological features, and associated with a poor prognosis. Currently, there is no standardized treatment protocol for SMARCA4-dNSCLC, as it generally exhibits a poor response to conventional chemotherapy regimens. Furthermore, the absence of typical driver gene mutations in lung cancer renders it insensitive to targeted therapies. We report the case of a 49-year-old Asian male patient with stage IV non-small cell lung cancer exhibiting SMARCA4 deficiency, who demonstrated a rapid response following treatment with a combination of nab-Paclitaxel, cisplatin, and bevacizumab. However, the patient ultimately experienced treatment failure due to disease progression from brain metastases, resulting in an overall survival (OS) of approximately 12 months. This case demonstrates the complicated clinical features of SMARCA4-deficient lung cancer, enriches the limited relevant clinical literature, and provides supplementary clinical data for this rare tumor subtype. While patients with SMARCA4-deficient lung cancer may benefit from chemotherapy combined with anti-angiogenic targeted therapy, the overall prognosis remains poor.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.